Antibiotic resistance is increasing among Staphylococcus saprophyticus strains isolated from urinary tract infection. This necessitates alternative therapies. For this, a lytic phage (vB_SsapS-104) against S. saprophyticus, which formed round and clear plaques on bacterial culture plates, was isolated from hospital wastewater and characterized. Microscopy analysis showed that it had a small head (about 50 nm), tail (about 80 nm), and a collar (about 22 nm in length and 19 nm in width) indicating to be a phage within Siphoviridae family. Phage vB_SsapS-104 showed a large latency period of about 40 min, rapid adsorption rate that was significantly enhanced by MgCl2 and CaCl2, and high stability to a wide range of temperatures and pH values. Restriction analyses demonstrated that phage consists of a double-stranded DNA with an approximate genome size of 40 Kb. BLAST results did not show high similarity (megablast) with other previously identified phages. But, in Blastn, similarity with Staphylococcus phages was observed. Phage vB_SsapS-104 represented high anti-bacterial activity against S. saprophyticus isolates in vitro as it was able to lyse 8 of the 9 clinical isolates (%88.8) obtained from a hospital in Gorgan, Iran. It was a S. saprophyticus-specific phage because no lytic activity was observed on some other pathogenic bacteria tested. Therefore, phage vB_SsapS-104 can be considered as a specific virulent phage against of S. saprophyitcus isolated from urinary tract infection. This study provided the partial genomic characterization of S. saprophyticus phage and its application against urinary tract infection associated with S. saprophyticus. This phage also can be considered as a good candidate for a therapeutic alternative in the future.

Department of Biology Faculty of Sciences University of Isfahan Isfahan 81746 73441 Iran

Laboratory Sciences Research Center Golestan University of Medical Sciences Gorgan 4934174515 Iran

See more in PubMed

Antimicrob Agents Chemother. 2001 Mar;45(3):649-59 PubMed

Appl Environ Microbiol. 2005 Apr;71(4):1836-42 PubMed

J Clin Microbiol. 2005 Jul;43(7):3390-7 PubMed

J Infect Chemother. 2005 Oct;11(5):211-9 PubMed

Lett Appl Microbiol. 2005;41(6):482-6 PubMed

Antimicrob Agents Chemother. 2006 Apr;50(4):1268-75 PubMed

J Clin Microbiol. 2007 May;45(5):1561-4 PubMed

Lett Appl Microbiol. 2007 Sep;45(3):313-7 PubMed

Obstet Gynecol Clin North Am. 2008 Jun;35(2):235-48, viii PubMed

Appl Environ Microbiol. 2009 Jul;75(13):4483-90 PubMed

Environ Microbiol. 2009 Nov;11(11):2775-7 PubMed

Curr Pharm Biotechnol. 2010 Jan;11(1):69-86 PubMed

BMC Microbiol. 2010 Apr 29;10:131 PubMed

FEMS Immunol Med Microbiol. 2010 Aug;59(3):447-55 PubMed

Int J Microbiol. 2010;2010:null PubMed

Appl Environ Microbiol. 2011 Feb;77(3):756-61 PubMed

Res Virol. 1990 Nov-Dec;141(6):625-35 PubMed

Arch Virol. 2012 Feb;157(2):225-34 PubMed

Bacteriophage. 2011 Mar;1(2):66-85 PubMed

BMC Genomics. 2012 Jun 08;13:228 PubMed

Adv Virus Res. 2012;83:143-216 PubMed

Future Microbiol. 2012 Oct;7(10):1147-71 PubMed

PLoS One. 2012;7(10):e46537 PubMed

Viruses. 2012 Dec;4(12):3316-35 PubMed

Virulence. 2014 Jan 1;5(1):226-35 PubMed

Arch Virol. 2014 Sep;159(9):2537-40 PubMed

Arch Virol. 2014 Nov;159(11):2909-15 PubMed

Mol Biol Rep. 2014 Sep;41(9):5829-38 PubMed

J Med Microbiol. 2015 Apr;64(Pt 4):454-62 PubMed

Bacteriophage. 2016 Aug 5;6(3):e1219440 PubMed

Virus Genes. 2017 Jun;53(3):464-476 PubMed

Ann Intern Med. 1985 Mar;102(3):342-3 PubMed

Res Virol. 1994 Mar-Apr;145(2):111-21 PubMed

Eur J Epidemiol. 1996 Feb;12(1):51-4 PubMed

Adv Virus Res. 1998;51:135-201 PubMed